

Ibrahim Halil Sahin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8501720/publications.pdf>

Version: 2024-02-01

20
papers

495
citations

1040056

9
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

743
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRAF</i> Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 191-197.	3.7	11
2	A phase I/IIb study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.	2.8	30
3	Human Epidermal Growth Factor Receptor 2â€œTargeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues. <i>JCO Oncology Practice</i> , 2022, 18, 545-554.	2.9	8
4	Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 1-12.	3.8	12
5	Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 735-742.	3.0	14
6	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 668-675.	3.7	20
7	<i>BRAF</i> Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues. <i>JCO Oncology Practice</i> , 2021, 17, 723-730.	2.9	20
8	Precision medicine for gastrointestinal cancers: a conference report. <i>Future Science OA</i> , 2020, 6, FSO478.	1.9	2
9	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. <i>JCO Oncology Practice</i> , 2020, 16, 319-325.	2.9	15
10	Clinical and molecular markers of immune checkpoint inhibitor (ICI) response in dMMR colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2020, 38, 225-225.	1.6	4
11	The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship. , 2020, 3, 699-709.		0
12	Immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer and other solid tumors: is it truly disease-agnostic?. <i>Colorectal Cancer</i> , 2020, 9, CRC29.	0.8	1
13	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , 2019, 121, 809-818.	6.4	232
14	Precision medicine for metastatic colorectal cancer: an evolving era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 919-931.	3.0	34
15	Pancreatic cancer microenvironment: a current dilemma. <i>Clinical and Translational Medicine</i> , 2019, 8, 2.	4.0	72
16	Fine-tuning immunotherapy in MMR-D/MSI-H colorectal cancer. <i>Colorectal Cancer</i> , 2019, 8, CRC12.	0.8	1
17	Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4116-4116.	1.6	9
18	Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 560-560.	1.6	2

#	ARTICLE	IF	CITATIONS
19	BRAF mutations as a therapeutic target in metastatic colorectal cancer patients: a long due success. Colorectal Cancer, 2019, 8, .	0.8	1
20	Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World Journal of Clinical Oncology, 2016, 7, 340.	2.3	7